Endoscopic Ultrasound-Guided Radiofrequency Ablation in the Management of Pancreatic Tumors: A Comprehensive Systematic Review and Meta-Analysis.

Authors

Sanket Basida, Muhammad Nadeem Yousaf, Chukwunonso Ezeani, Drew Nannini, Parit Zalavadia, Madhav Changela, Dushyant Singh Dahiya, Shyam Thakkar

Published in

Gastro hep advances. Volume 5. Issue 10. Pages 101066. Epub Jul 18, 2026.

Abstract

Radiofrequency ablation (RFA) is a proven therapy for solid organ tumors. Endoscopic ultrasound-guided RFA (EUS-RFA) is a less invasive, emerging technique that may serve as an alternative to surgical resection for unresectable pancreatic tumors (UPT). However, its efficacy, safety, and clinical outcomes in tumor subgroups remain unclear. This systematic review and meta-analysis evaluate the efficacy, clinical, and technical success (TS) of EUS-RFA for UPT.
A comprehensive search of PubMed, Web of Science, Embase, Cochrane, and Clinicaltrials.gov (as of April 2025) identified studies on EUS-RFA and pancreatic tumors. Primary outcomes were TS, defined as probe placement and ablation regardless of outcome, and clinical success (CS), defined as symptomatic improvement or tumor size reduction with necrosis. Secondary outcomes included adverse events and efficacy for tumor subtypes. A pooled analysis using random-effect modeling was performed using the metafor R package.
Seventeen studies involving 168 patients (52.38% female) and 182 tumors were included. Tumors included pancreatic neuroendocrine tumors (106, 58.24%), pancreatic ductal adenocarcinomas (49, 26.92%), and others. Tumors were located primarily in the body, neck, or tail (54.02%). Average ablation sessions per patient were 1.1. Pooled TS and CS rates were 89% and 84%, respectively. Nonfunctional neuroendocrine tumors and mixed type showed the highest CS rate (91%). The most common adverse event included abdominal pain (6.5%) and hyperamylasemia (3.6%).
EUS-RFA is a promising, safe modality for managing UPT, with high TS (89%) and CS (84%) rates. Larger clinical trials are needed to confirm safety, outcomes, and survival benefits for pancreatic cancer subtypes.

PMID:
42668514
Bibliographic data and abstract were imported from PubMed on 30 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.